Cortexin is a Russian drug made from peptides of the animal cerebral cortex. It is studied in stroke, head injuries, and pediatric neurology as a way to protect nerve cells.
A polypeptide complex from bovine/porcine cerebral cortex. Contains neuropeptides <10 kDa. 10 mg/vial for IM administration. Registered in Russia and CIS countries.
A neuroprotective agent with clinical data in acute ischemic stroke (3 RCTs at Russian centers), TBI, and pediatric neurology (cerebral palsy, developmental delays, epilepsy). Restores the neuronal balance of inhibitory/excitatory neurotransmitters.
↑BDNF, NGF → neuroplasticity. ↑GABA/glutamate balance → ↓neuronal excitation in epilepsy. ↑antioxidant enzymes (SOD, catalase) → ↓oxidative stress in the brain. ↑dopamine and serotonin in the cortex.
Studies used 10 mg IM once a day (adults) or 0.5 mg/kg (children) for a 10-day course; a repeat course was given after 3-6 months. The solution was prepared with bacteriostatic water (1-2 mL).
Level A Human clinical trials. There are randomized controlled trials (RCTs), or the compound has been approved by a regulatory agency. The most reliable level. 3 RCTs in stroke. Registered in Russia/CIS.
⚠️ IM administration only. Much of the data comes from Russian centers and does not always meet Western GCP standards. Prescription drug.
Research peptides are laboratory reagents (Research Use Only). They are not medicines and are not intended for use in humans or animals.